Sarepta, Biogen Drugs With Accelerated Approval Under Fire in FDA Report

Seeking Alpha05:57

Needham Reiterates Buy on Sarepta Therapeutics, Maintains $202 Price Target

BenzingaJan 14 21:14 · Ratings

Sarepta Therapeutics Analyst Ratings

BenzingaJan 14 21:13 · Ratings

A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $182 to $217

Futu NewsJan 14 21:00 · Ratings

Sarepta Therapeutics (SRPT) Gets a Buy From Piper Sandler

TipRanksJan 14 19:57 · Ratings

Sarepta Therapeutics: Strong Elevidys Launch and Promising Pipeline Drive Buy Rating

TipRanksJan 14 03:56 · Ratings